183 related articles for article (PubMed ID: 12188168)
1. Population-based persistency rates for topical glaucoma medications measured with pharmacy claims data.
Dasgupta S; Oates V; Bookhart BK; Vaziri B; Schwartz GF; Mozaffari E
Am J Manag Care; 2002 Aug; 8(10 Suppl):S255-61. PubMed ID: 12188168
[TBL] [Abstract][Full Text] [Related]
2. Discontinuation rates of topical glaucoma medications in a managed care population.
Shaya FT; Mullins CD; Wong W; Cho J
Am J Manag Care; 2002 Aug; 8(10 Suppl):S271-7. PubMed ID: 12188170
[TBL] [Abstract][Full Text] [Related]
3. Rates of discontinuation and change of glaucoma therapy in a managed care setting.
Spooner JJ; Bullano MF; Ikeda LI; Cockerham TR; Waugh WJ; Johnson T; Mozaffari E
Am J Manag Care; 2002 Aug; 8(10 Suppl):S262-70. PubMed ID: 12188169
[TBL] [Abstract][Full Text] [Related]
4. Measuring persistency and intraocular pressure-controlled days in patients receiving topical glaucoma medications.
Schwartz GF; Platt R
Am J Manag Care; 2002 Aug; 8(10 Suppl):S278-80. PubMed ID: 12188171
[TBL] [Abstract][Full Text] [Related]
5. Switching from latanoprost to fixed-combination latanoprost-timolol: a 21-day, randomized, double-masked, active-control study in patients with glaucoma and ocular hypertension.
Olander K; Zimmerman TJ; Downes N; Schoenfelder J;
Clin Ther; 2004 Oct; 26(10):1619-29. PubMed ID: 15598478
[TBL] [Abstract][Full Text] [Related]
6. Medication adherence and health care costs with the introduction of latanoprost therapy for glaucoma in a Medicare managed care population.
Bhosle MJ; Reardon G; Camacho FT; Anderson RT; Balkrishnan R
Am J Geriatr Pharmacother; 2007 Jun; 5(2):100-11. PubMed ID: 17719512
[TBL] [Abstract][Full Text] [Related]
7. Persistence and adherence with topical glaucoma therapy.
Nordstrom BL; Friedman DS; Mozaffari E; Quigley HA; Walker AM
Am J Ophthalmol; 2005 Oct; 140(4):598-606. PubMed ID: 16226511
[TBL] [Abstract][Full Text] [Related]
8. A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%.
Maul E; Carrasco FG; Costa VP; Casiraghi JF; Vargas E; Sarmina JS; Mayol R
Clin Ther; 2007 Sep; 29(9):1915-23. PubMed ID: 18035191
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of practice patterns for the care of open-angle glaucoma compared with claims data: the Glaucoma Adherence and Persistency Study.
Quigley HA; Friedman DS; Hahn SR
Ophthalmology; 2007 Sep; 114(9):1599-606. PubMed ID: 17572498
[TBL] [Abstract][Full Text] [Related]
10. Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the Glaucoma Adherence and Persistency Study (GAPS).
Friedman DS; Quigley HA; Gelb L; Tan J; Margolis J; Shah SN; Kim EE; Zimmerman T; Hahn SR
Invest Ophthalmol Vis Sci; 2007 Nov; 48(11):5052-7. PubMed ID: 17962457
[TBL] [Abstract][Full Text] [Related]
11. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy?
Robin AL; Covert D
Ophthalmology; 2005 May; 112(5):863-8. PubMed ID: 15878067
[TBL] [Abstract][Full Text] [Related]
12. A gap analysis approach to assess patient persistence with glaucoma medication.
Lee PP; Walt JG; Chiang TH; Guckian A; Keener J
Am J Ophthalmol; 2007 Oct; 144(4):520-4. PubMed ID: 17692273
[TBL] [Abstract][Full Text] [Related]
13. The influence of diclofenac ophthalmic solution on the intraocular pressure-lowering effect of topical 0.5% timolol and 0.005% latanoprost in primary open-angle glaucoma patients.
Costagliola C; Parmeggiani F; Antinozzi PP; Caccavale A; Cotticelli L; Sebastiani A
Exp Eye Res; 2005 Nov; 81(5):610-5. PubMed ID: 15949795
[TBL] [Abstract][Full Text] [Related]
14. Accounting for restart rates in evaluating persistence with ocular hypotensives.
Schwartz GF; Platt R; Reardon G; Mychaskiw MA
Ophthalmology; 2007 Apr; 114(4):648-52. PubMed ID: 17398318
[TBL] [Abstract][Full Text] [Related]
15. Patient persistency with topical ocular hypotensive therapy in a managed care population.
Reardon G; Schwartz GF; Mozaffari E
Am J Ophthalmol; 2004 Jan; 137(1 Suppl):S3-12. PubMed ID: 14697909
[TBL] [Abstract][Full Text] [Related]
16. A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy.
Denis P; Lafuma A; Khoshnood B; Mimaud V; Berdeaux G
Curr Med Res Opin; 2007 Mar; 23(3):601-8. PubMed ID: 17355741
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the nocturnal effects of once-daily timolol and latanoprost on intraocular pressure.
Liu JH; Kripke DF; Weinreb RN
Am J Ophthalmol; 2004 Sep; 138(3):389-95. PubMed ID: 15364220
[TBL] [Abstract][Full Text] [Related]
18. Measurement of persistence and adherence to regimens of IOP-lowering glaucoma medications using pharmacy claims data.
Wilensky J; Fiscella RG; Carlson AM; Morris LS; Walt J
Am J Ophthalmol; 2006 Jan; 141(1 Suppl):S28-33. PubMed ID: 16389058
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and safety of dorzolamide-timolol alone or combined with latanoprost in open-angle glaucoma or ocular hypertension.
Lesk MR; Koulis T; Sampalis F; Sampalis JS; Bastien NR
Ann Pharmacother; 2008 Apr; 42(4):498-504. PubMed ID: 18364402
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines.
Stewart WC; Konstas AG; Nelson LA; Kruft B
Ophthalmology; 2008 Jul; 115(7):1117-1122.e1. PubMed ID: 18082886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
